GemPharmatech Co., Ltd. (SHA:688046)
China · Delayed Price · Currency is CNY 29.79
-0.78 (-2.55%)
At close: Sep 11, 2026
GemPharmatech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 12,189 | 6,298 | 5,249 | 8,262 | 9,861 | - | |
Market Cap Growth | 56.11% | 19.98% | -36.46% | -16.22% | - | - |
Enterprise Value | 11,266 | 5,427 | 4,152 | 7,195 | 8,681 | - |
Last Close Price | 29.79 | 15.19 | 12.59 | 19.43 | 23.15 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 65.96 | 44.15 | 47.80 | 51.99 | 59.88 | - |
Forward PE | 60.80 | 43.06 | 23.62 | 36.05 | 40.76 | - |
PS Ratio | 13.88 | 7.94 | 7.64 | 13.28 | 19.09 | - |
PB Ratio | 5.38 | 2.83 | 2.46 | 3.89 | 4.99 | - |
P/TBV Ratio | 5.55 | 2.92 | 2.52 | 3.98 | 5.11 | - |
P/FCF Ratio | 52.90 | 51.60 | - | - | - | - |
P/OCF Ratio | 40.66 | 27.74 | 58.12 | 70.87 | 93.04 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 12.83 | 6.84 | 6.05 | 11.56 | 16.81 | - |
EV/EBITDA Ratio | 40.09 | 24.04 | 25.06 | 45.71 | 63.98 | - |
EV/EBIT Ratio | 60.04 | 35.64 | 45.22 | 64.57 | 88.23 | - |
EV/FCF Ratio | 48.90 | 44.47 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.10 | 0.13 | 0.06 | 0.06 | 0.01 | 0.03 |
Debt / EBITDA Ratio | 0.83 | 1.22 | 0.75 | 0.74 | 0.13 | 0.20 |
Debt / FCF Ratio | 1.01 | 2.39 | - | - | - | 1.04 |
Net Debt / Equity Ratio | -0.41 | -0.44 | -0.48 | -0.56 | -0.60 | -0.60 |
Net Debt / EBITDA Ratio | -3.49 | -4.32 | -6.25 | -7.60 | -8.81 | -3.79 |
Net Debt / FCF Ratio | -4.00 | -8.00 | 44.35 | 13.39 | 14.17 | -19.56 |
Asset Turnover | 0.31 | 0.29 | 0.27 | 0.26 | 0.31 | 0.41 |
Inventory Turnover | 4.04 | 4.55 | 5.16 | 4.20 | 3.78 | 4.27 |
Quick Ratio | 3.38 | 3.14 | 4.11 | 4.35 | 6.55 | 3.43 |
Current Ratio | 3.63 | 3.32 | 4.61 | 4.52 | 6.85 | 3.69 |
Return on Equity (ROE) | 8.23% | 6.54% | 5.16% | 7.75% | 11.92% | 17.32% |
Return on Assets (ROA) | 4.16% | 3.50% | 2.23% | 2.88% | 3.72% | 6.22% |
Return on Invested Capital (ROIC) | 11.57% | 11.21% | 8.35% | 12.83% | 17.05% | 37.38% |
Return on Capital Employed (ROCE) | 7.90% | 6.50% | 4.20% | 5.00% | 4.80% | 11.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.50% | 2.27% | 2.09% | 1.92% | 1.67% | - |
FCF Yield | 1.89% | 1.94% | -0.45% | -1.08% | -0.85% | - |
Dividend Yield | 0.71% | 1.45% | 1.11% | 0.82% | 0.18% | - |
Payout Ratio | 75.30% | 42.92% | 72.95% | 11.24% | 0.17% | 0.54% |
Buyback Yield / Dilution | 2.46% | -0.19% | 0.18% | -3.93% | -9.84% | 1.93% |
Total Shareholder Return | 3.17% | 1.25% | 1.29% | -3.11% | -9.66% | 1.93% |